KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Ratio (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Equity Ratio for 16 consecutive years, with 0.19 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 42.08% year-over-year to 0.19, compared with a TTM value of 0.19 through Dec 2025, up 42.08%, and an annual FY2025 reading of 0.19, up 42.08% over the prior year.
  • Equity Ratio was 0.19 for Q4 2025 at Teva Pharmaceutical Industries, up from 0.18 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.24 in Q3 2021 and bottomed at 0.14 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.19, with a median of 0.19 recorded in 2022.
  • The sharpest move saw Equity Ratio fell 26.9% in 2024, then soared 42.08% in 2025.
  • Year by year, Equity Ratio stood at 0.24 in 2021, then dropped by 17.18% to 0.2 in 2022, then dropped by 4.33% to 0.19 in 2023, then dropped by 26.9% to 0.14 in 2024, then surged by 42.08% to 0.19 in 2025.
  • Business Quant data shows Equity Ratio for TEVA at 0.19 in Q4 2025, 0.18 in Q3 2025, and 0.17 in Q2 2025.